Steven Cohen's BCRX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.21 M shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $9.47 M, representing 0.01% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in BCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2019, adding 5.12 M shares. Largest reduction occurred in Q1 2020, reducing 5.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +975,389 | Add 409.51% | 1.21 M | $7.80 |
| Q3 2025 | +238,187 | New Buy | 238,187 | $7.59 |
| Q2 2024 | -1.62 M | Sold Out | 0 | $0.00 |
| Q1 2024 | +1.62 M | New Buy | 1.62 M | $5.08 |
| Q4 2023 | -2.76 M | Sold Out | 0 | $0.00 |
| Q3 2023 | -1.25 M | Reduce 31.11% | 2.76 M | $7.08 |
| Q2 2023 | +3.95 M | Add 7385.42% | 4 M | $7.04 |
| Q1 2023 | -1.94 M | Reduce 97.31% | 53,500 | $8.34 |
| Q4 2022 | +1.99 M | New Buy | 1.99 M | $11.48 |
| Q3 2022 | -644,100 | Sold Out | 0 | $0.00 |
| Q2 2022 | +644,100 | New Buy | 644,100 | $10.58 |
| Q1 2022 | -25,272 | Sold Out | 0 | $0.00 |
| Q4 2021 | -178,641 | Reduce 87.61% | 25,272 | $13.85 |
| Q3 2021 | +203,913 | New Buy | 203,913 | $14.37 |
| Q1 2021 | -3.23 M | Sold Out | 0 | $0.00 |
| Q4 2020 | +2.6 M | Add 410.72% | 3.23 M | $7.45 |
| Q3 2020 | -254,970 | Reduce 28.73% | 632,600 | $3.44 |
| Q2 2020 | -2.13 M | Reduce 70.59% | 887,570 | $4.76 |
| Q1 2020 | -5.36 M | Reduce 64.00% | 3.02 M | $2.00 |
| Q4 2019 | +5.12 M | Add 157.14% | 8.38 M | $3.45 |
| Q3 2019 | +3.26 M | New Buy | 3.26 M | $2.87 |
| Q2 2019 | -47,453 | Sold Out | 0 | $0.00 |
| Q1 2019 | -302,547 | Reduce 86.44% | 47,453 | $8.13 |
| Q4 2018 | +350,000 | New Buy | 350,000 | $8.07 |
| Q1 2018 | -933,766 | Sold Out | 0 | $0.00 |
| Q4 2017 | +933,766 | New Buy | 933,766 | $4.91 |
| Q3 2015 | -2,000 | Sold Out | 0 | $0.00 |
| Q2 2015 | +2,000 | New Buy | 2,000 | $15.00 |
Steven Cohen's BioCryst Pharmaceuticals Investment FAQs
Steven Cohen first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q2 2015, acquiring 2,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held BioCryst Pharmaceuticals, Inc. (BCRX) for 28 quarters since Q2 2015.
Steven Cohen's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q4 2019, adding 8,382,900 shares worth $28.92 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,213,576 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $9.47 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 8,382,900 shares, as reported at the end of Q4 2019.